Related Topics News -

     
 < Previous page   Title only   |   Print 
     
中國抗體撤回舒西利單抗用於治療RA上市申請

2025-07-14T  
中國抗體中國區總裁離任

2025-06-08T  
中國抗體折讓11.29%發新股 籌淨額1.24億元

2025-05-14T  
中國抗體SM17治療特異性皮炎臨床試驗積極頂線結果

2025-04-08T  
《業績》中國抗體全年虧損收窄至1.85億人民幣

2025-03-31T  
中國抗體SM17中國1b期臨床試驗完成全部患者入組

2024-12-09T  
《業績》中國抗體-B中期虧損收窄至9,062萬人民幣

2024-08-20T  
 < Previous page 

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2026 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.